NCT03096080View on ClinicalTrials.gov

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 24, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Polycystic Kidney, Autosomal Recessive
Interventions
DRUG

Tesevatinib

One dose of the study drug in liquid form

Trial Locations (2)

19104

Children's Hospital of Philadelphia, Philadelphia

53226

Children's Hospital of Wisconsin, Milwaukee

All Listed Sponsors
lead

Kadmon Corporation, LLC

INDUSTRY

NCT03096080 - A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD) | Biotech Hunter | Biotech Hunter